Novo Nordisk's 20%+ price drop since yesterday following a significant downgrade in sales and profit guidance is a great buying opportunity. The stock's forward P/E is at half the stock's five-year av...Looker's approach to data modeling simplifies data access and interpretation, making it easier for both technical and business users to explor